Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -10% Improvement Relative Risk ICU admission -110% Hospitalization time -10% c19aspirin.com Sullerot et al. Aspirin for COVID-19 Prophylaxis Favors aspirin Favors control
Sullerot, 1,047 patient aspirin prophylaxis study: 10% higher mortality [p=0.52], 110% higher ICU admission [p=0.007], and 10% longer hospitalization [p=0.02] https://c19p.org/sullerot
copied to clipboard
Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia
Sullerot et al., GeroScience, doi:10.1007/s11357-021-00499-8
7 Jan 2022    Source   PDF   Share   Tweet
Retrospective 1,047 pneumonia patients in 5 COVID-19 geriatric units in France and Switzerland, significantly higher ICU admission and longer hospital stays with existing aspirin treatment. Numbers in this study appear to be inconsistent, for example the abstract says 147 of 301 aspirin patients died, shown as 34.3%, while Table 1 shows 104 of 301 (34.6%).
risk of death, 10.0% higher, RR 1.10, p = 0.52, treatment 101 of 301 (33.6%), control 224 of 746 (30.0%).
risk of ICU admission, 109.7% higher, RR 2.10, p = 0.007, treatment 22 of 301 (7.3%), control 26 of 746 (3.5%).
hospitalization time, 10.0% higher, relative time 1.10, p = 0.02, treatment 301, control 746.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sullerot et al., 1/7/2022, retrospective, inverse propensity weighting, multiple countries, multiple regions, peer-reviewed, 15 authors, study period 1 March, 2020 - 31 December, 2020.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit